{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:18Z","timestamp":1753891518372,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>A rare autosomal recessive genetic disease is spinal muscular atrophy with respiratory distress type 1 (SMARD 1; OMIM #604320), which is characterized by progressive distal limb muscle weakness, muscular atrophy, and early onset of respiratory failure. Herein, we report the case of a 4-month-old female infant with SMARD type 1 who was admitted to our hospital owing to unexplained distal limb muscle weakness and early respiratory failure. This report summarizes the characteristics of SMARD type 1 caused by heterozygous variation in the immunoglobulin mu DNA binding protein 2 (IGHMBP2) gene by analyzing its clinical manifestations, genetic variation characteristics, and related examinations, aiming to deepen clinicians\u2019 understanding of the disease, assisting pediatricians in providing medical information to parents and improving the decision-making process involved in establishing life support.<\/jats:p>","DOI":"10.3389\/fneur.2024.1289625","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T05:14:55Z","timestamp":1717046095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Heterozygous variation in the IGHMBP2 gene leading to spinal muscular atrophy with respiratory distress type 1"],"prefix":"10.3389","volume":"15","author":[{"given":"Chaoai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nmd.2018.10.002","article-title":"Spinal muscular atrophy with respiratory distress type 1: a multicenter retrospective study","volume":"29","author":"Viguier","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e164608","DOI":"10.1172\/jci.insight.164608","article-title":"ABT1 modifies SMARD1 pathology via interactions with IGHMBP2 and stimulation of ATPase and helicase activity","volume":"8","author":"Vadla","year":"2023","journal-title":"JCI Insight"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s00018-020-03492-0","article-title":"Current understanding of and emerging treatment options for spinal muscular atrophy with respiratory distress type 1 (SMARD1)","volume":"77","author":"Perego","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.24953\/turkjped.2020.2012","article-title":"Spinal muscular atrophy with respiratory distress type 1 (SMARD1): a rare cause of hypotonia, diaphragmatic weakness, and respiratory failure in infants","volume":"64","author":"Pekuz","year":"2022","journal-title":"Turk J Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4103\/aian.AIAN_680_20","article-title":"Early infantile onset non-5q spinal muscular atrophies: a diagnostic odyssey","volume":"24","author":"Suthar","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/mxe.mxe_8_21","article-title":"Case of autosomal-recessive spinal muscular atrophy with respiratory distress type 1 caused by compound heterozygous mutations in immunoglobulin-binding protein 2 gene: expansion in clinical features","volume":"2","author":"Khairata","year":"2022","journal-title":"Middle East J Med Genet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.nmd.2018.09.008","article-title":"Charcot Marie tooth disease type 2S with late onset diaphragmatic weakness: an atypical case","volume":"28","author":"Kulshrestha","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.29271\/jcpsp.2021.12.1494","article-title":"Spinal muscular atrophy with respiratory distress type 1: a novel variant of IGHMBP2 gene","volume":"31","author":"Saeed","year":"2021","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ajhg.2014.10.002","article-title":"Truncating and missense mutations in IGHMBP2 cause Charcot-Marie tooth disease type 2","volume":"95","author":"Cottenie","year":"2014","journal-title":"Am J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/biology12060867","article-title":"In vitro modeling as a tool for testing therapeutics for spinal muscular atrophy and IGHMBP2-related disorders","volume":"12","author":"Sierra-Delgado","year":"2023","journal-title":"Biology (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.spen.2021.100878","article-title":"Spinal muscular atrophy","volume":"37","author":"Nicolau","year":"2021","journal-title":"Semin Pediatr Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy-insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ejmg.2018.04.001","article-title":"An atypical phenotype of a patient with infantile spinal muscular atrophy with respiratory distress type 1 (SMARD 1)","volume":"61","author":"Wu","year":"2018","journal-title":"Eur J Med Genet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.braindev.2016.02.001","article-title":"Infantile spinal muscular atrophy with respiratory distress type I presenting without respiratory involvement: novel mutations and review of the literature","volume":"38","author":"Luan","year":"2016","journal-title":"Brain and Development"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1007051","DOI":"10.3389\/fneur.2023.1007051","article-title":"Case report: a novel homozygous histidine triad nucleotide-binding protein 1 mutation featuring distal hereditary motor-predominant neuropathy with rimmed vacuoles","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2169\/internalmedicine.6396-20","article-title":"Spinal muscular atrophy type 3 showing a specific pattern of selective vulnerability on muscle ultrasound","volume":"60","author":"Nakamura","year":"2021","journal-title":"Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejpn.2011.10.005","article-title":"Infantile spinal muscular atrophy with respiratory distress type I (SMARD 1): an atypical phenotype and review of the literature","volume":"16","author":"Messina","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nmd.2008.11.013","article-title":"Interfamilial phenotypic heterogeneity in SMARD1","volume":"19","author":"Joseph","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/hmg\/ddi189","article-title":"Treatment with trkC agonist antibodies delays disease progression in neuromuscular degeneration (nmd) mice","volume":"14","author":"Ruiz","year":"2005","journal-title":"Hum Mol Genet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.stemcr.2014.06.004","article-title":"iPSC-derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1","volume":"3","author":"Simone","year":"2014","journal-title":"Stem Cell Reports"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a Mouse Model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol Ther"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1289625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T05:14:57Z","timestamp":1717046097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1289625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":23,"alternative-id":["10.3389\/fneur.2024.1289625"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1289625","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1289625"}}